Navigation Links
Cancer Immunotherapy Expert Joins Pacific Meso Center Research Team
Date:6/8/2012

LOS ANGELES, June 8, 2012 /PRNewswire/ -- The Pacific Meso Center (PMC) announces the appointment of its new scientific researcher for its laboratory on Santa Monica Boulevard. A graduate of the University of Southern California, Dr. Raymond M. Wong, Ph.D. joins the center after 5 years with MannKind Corporation, where he worked in cancer immunotherapy and specifically on preclinical development for MannKind's MKC-1106-MT and MKC-1106-PP cancer vaccine programs.

At PMC, Dr. Wong, who has a Ph.D. in immunology and whose work has been published in many scientific journals, will be responsible for planning and conducting the research on malignant pleural mesothelioma, an asbestos-related cancer affecting the pleura - the lining of the chest cavity. Dr. Robert B. Cameron, M.D., scientific advisor at PMC, stated, "Dr. Wong comes highly recommended and is an outstanding scientist with the research knowledge in immunology and immunotherapy who will help PMC develop promising immunotherapy treatments for mesothelioma patients at a time when immunotherapy has again become a focus of research for many cancers. He will be collaborating with Dr. Dongmei Hou of the Punch Worthington Research Laboratory at UCLA and with Dr. Saroj Basak of the Veterans Administration Medical Center in West Los Angeles." 

Dr. Wong also will collaborate with PMC's Scientific Advisor, Dr. Robert B. Cameron, who is a board certified cardiothoracic surgeon and surgical oncologist, the director of the UCLA Comprehensive Mesothelioma Program at the David Geffen School of Medicine at UCLA, Chief of Thoracic Surgery at the West Los Angeles Veterans Administration Medical Center, and a long-time proponent of lung-sparing surgery for malignant pleural mesothelioma. Together Drs. Wong and Cameron will work to advance therapeutic cancer immunotherapy strategies from pre-clinical stages to phase I/II clinical trials.

About Pacific Meso Center

The Pacific Meso Center (PMC), a division of The Pacific Heart, Lung & Blood Institute, was established in 2002 with the goal of becoming the most innovative research and treatment organization in the world for patients with malignant pleural mesothelioma (MPM), a rare form of cancer related to asbestos exposure. PMC focuses on specific areas of research that improve mesothelioma victims' lives and longevity, particularly those promising treatments that approach MPM as a chronic, treatable disease. The ultimate goal of PMC is finding a cure for mesothelioma.

For further information, please contact:

Clare Cameron
The Pacific Meso Center
310-478-4678
ccameron@phlbi.org
http://www.pacificmesocenter.org          

 

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

 


'/>"/>
SOURCE The Pacific Meso Center
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
3. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
4. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
5. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
6. Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS
7. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
10. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
11. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):